Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23024014 | 0.87 | MEN1 (0.52) | LMNANOTUMALDH1A1HPGDMEN1 | |
| SCHEMBL7055587 | 0.83 | RPA1 (0.51) | ALDH1A1HPGDMEN1KMT2ATP53 | |
| SCHEMBL31587999 | 0.80 | POLB (0.58) | LMNANOTUMALDH1A1MEN1KMT2A | |
| SCHEMBL31587696 | 0.79 | NOTUM (0.47) | LMNANOTUMMEN1KMT2ATP53 | |
| SCHEMBL1063920 | 0.79 | CYP2C9 (0.61) | LMNAALDH1A1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL15755051 | 0.79 | KEAP1 (0.47) | NOTUMMEN1KMT2ANPC1MGLL | |
| SCHEMBL4509431 | 0.79 | RPA1 (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2ALKBH5 | |
| SCHEMBL182362 | 0.79 | STIM1 (0.57) | LMNAALDH1A1RAB9ANPC1THRB | |
| SCHEMBL182223 | 0.79 | CYP2C8 (0.51) | LMNAALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL15352892 | 0.78 | NOTUM (0.55) | LMNANOTUMALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112166110-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LMNA 4719/4885NOTUM 4201/4885ALDH1A1 3280/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LMNA 4719/4885NOTUM 4201/4885ALDH1A1 3280/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | LMNA 4719/4885NOTUM 4201/4885ALDH1A1 3280/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | LMNA 4618/4885NOTUM 4040/4885ALDH1A1 3858/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LMNA 4719/4885NOTUM 4201/4885ALDH1A1 3280/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | LMNA 4719/4885NOTUM 4201/4885ALDH1A1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.